Ah, the stock market. That bastion of calm, predictable rationality. Or, at least, it used to be, before former President Donald J. Trump decided it was just another stage for his particular brand of economic theater. In the grand tradition of reality television, every policy pronouncement, every diplomatic handshake, and certainly every late-night Truth Social missive, seems designed to send analysts scrambling and algorithms whirring. As November 2025 draws to a close, the market continues its exhilarating dance to the Trumpian beat, a symphony of “deals,” “threats,” and the occasional, bewildering policy pivot.
The Tariff Tango: Two Steps Forward, One Step Back (Sometimes Sideways)
Remember tariffs? Of course, you do. They’re like that recurring guest star who never quite leaves the show. Just this week, the former President was busy announcing when he “hopes to issue $2,000 tariff rebate checks,” a concept that has drawn “Republican resistance” and warnings of “inflationary bubbles”. Because nothing says economic stability like a government-issued rebate for taxes the government itself imposed.
But let’s rewind a bit. The market’s relationship with Trump’s tariff pronouncements is, shall we say, complicated. Take, for instance, the recent threats to impose “heavy tariffs on copper and drugs.” Back on September 7, 2025, when these were initially proposed (50% on copper, a whopping 200% on pharmaceuticals, with the latter eyed for 2026 to give domestic manufacturers a head start), the Dow Jones futures actually gained 77 points, and S&P 500 futures rose 0.17%. Apparently, the prospect of boosting domestic manufacturing was enough to make investors overlook the impending price hikes. Fast forward to July 8, 2025, when the same threats were reiterated, and Wall Street ended “slightly lower,” with the Dow Jones (DJI) down 0.4%, the S&P 500 (SP500) closing -0.1%, and the Nasdaq Composite (COMP:IND) remaining “unchanged”. Copper futures, however, had a field day, surging to a “record high,” up around 10%. Analyst Victoria Fernandez of Crossmark Global Investments observed the market was “somewhat shaking it off,” in a “wait and see mode,” a testament to the market’s learned resilience, or perhaps just sheer exhaustion.
Then there’s the great beef tariff saga. On November 14, 2025, the administration, in a stunning pivot to tackle “rising grocery prices,” rolled back tariffs on over 100 imported food products, including beef. This came after an earlier announcement on October 16, 2025, to simply “lower beef prices for consumers,” which sent live and feeder cattle futures plummeting to “limit down” the next day as speculative traders liquidated positions, despite no fundamental shift in supply or demand. Adding insult to injury for domestic producers, the Trump administration also “quadrupled the Tariff Rate Quota for beef imports from Argentina” from 20,000 to 80,000 metric tons, a move that “triggered additional selling in cattle futures”. Unsurprisingly, ranchers were “hit hard”. It’s almost as if tariffs, or their sudden removal, have consequences beyond the soundbite.
The Semiconductor Shuffle: A Delay, Not a Denial
In a rare moment of what some might call “prudence,” the Trump administration’s “semiconductor tariff plan” appears to be “likely delayed”. Why the sudden hesitation on a policy that would undoubtedly “boost domestic manufacturing”? Apparently, the reasons include “avoiding provoking China,” preserving a “current trade truce,” and, heaven forbid, concerns about “rising consumer prices”. The market, ever the optimist, seemed to take this as good news. Intel (INTC), a bellwether for the chip sector, closed up 2.27% at $35.11 on November 19, 2025, with pre-market trading showing a further 1.37% gain to $35.59. Because nothing says stability like a policy delay driven by geopolitical tightropes and the looming threat of an unhappy holiday shopping season.
Big Pharma’s Pain, Consumers’ Gain (Maybe): The Drug Price Dilemma
The pharmaceutical industry, ever a favorite punching bag, found itself in the crosshairs again. On May 12, 2025, President Trump announced plans to sign an executive order to “reduce prescription drug prices by 30%-80%”. The reaction was swift and predictable: pharmaceutical stocks tumbled. AstraZeneca (AZN) saw shares fall as much as 5%, while GSK (GSK) dropped 3.2% in London. Across the pond, Denmark’s Novo Nordisk (NVO) plummeted 7.5%, and Swiss giant Roche Holdings (ROG) fell 3.6%. Even American heavyweights like Eli Lilly (LLY), Pfizer (PFE), AbbVie (ABBV), and Merck (MRK) were all down roughly 2% to 3% in pre-market trading.
More recently, in November 2025, the administration announced a plan with Eli Lilly and Novo Nordisk to lower weight loss drug prices to a more palatable $149 per month, with Medicare set to cover these drugs. While this sounds like a win for waistlines and wallets, analysts at Goldman Sachs are already projecting a flattening of the growth trajectory for these companies, with revenue potentially not hitting the $100 billion mark by 2030. Because when the government gets involved, even miracle drugs can face a dose of market reality.
The Fed Follies: A Presidential Power Play
Perhaps the most reliable source of market jitters and analyst head-scratching comes from the former President’s relationship with the Federal Reserve. It’s a love-hate affair, mostly hate when interest rates aren’t exactly where he wants them. Just this week, Trump “threatened to fire Treasury Secretary Scott Bessent and Fed Chair Jerome Powell” over what he perceives as excessively high interest rates. In a moment of pure political theater, he publicly “joked (we think) about firing Treasury Secretary Scott Bessent while Bessent was sitting right in front of him”.
The market, however, tends to take these pronouncements with a degree of trepidation. Treasury Secretary Bessent himself reportedly “urged Trump not to fire Powell,” citing the very real risk of “harm to the financial market” and plunging the Federal Reserve into “uncharted legal and political territory”. Deutsche Bank, ever the pragmatist, projected that a Powell dismissal could lead to the “US dollar dropping 3-4% within 24 hours” and a “30-40 basis points sell-off” in US fixed income. An MSNBC opinion piece from April 22, 2025, bluntly stated that Trump’s threats could “throw the world economy into upheaval,” causing a “weakening dollar,” “surging gold,” and “rising 10-year Treasury yields,” all classic indicators of investor nervousness. It seems that even the most bombastic rhetoric can’t quite convince the markets that central bank independence is merely a suggestion.
Global Deals and Domestic Distractions
Amidst the tariff drama and Fed threats, there are, of course, “deals.” President Trump recently announced “partnerships with Saudi Arabia,” where Crown Prince Mohammed bin Salman pledged a cool “up to $1 trillion in US investment,” covering everything from AI and semiconductor support to the sale of F-35 fighter jets. While the specifics of these “trillion-dollar questions” remain somewhat vague, the optics of such grand pronouncements are, as always, impeccable.
Further afield, the administration secured “multiple new U.S.-Asia trade deals and foreign investment commitments”. October 2025 saw trade arrangements with Malaysia, Thailand, Vietnam, and Cambodia, focusing on reciprocal tariff reductions and market access. And in a moment of genuine de-escalation, a US-China trade deal formalized on November 1, 2025, included a “tariff truce,” commitments on fentanyl control, the removal of rare earth export controls, and China opening its market to US agricultural exports while suspending retaliatory tariffs. For a moment, the trade war seemed to be taking a much-needed nap.
Domestically, the former President also announced “steps to dismantle Department of Education”. This involved handing off “some of its biggest grant programs to other federal agencies,” a move that opponents warn could “disrupt programs that support some of the nation’s most vulnerable student populations”. While the direct stock market impact here is less clear, one can only imagine the administrative chaos this promises, a true testament to the “drain the swamp” philosophy.
Truth Social and the Volatility Index
And finally, we have Truth Social, the platform where the former President’s unfiltered thoughts often first see the light of day. His “lengthy post on Truth Social” focusing on “Democrats who… market and those hesitant to make a move focusing on the risks posed by…” serves as a constant reminder that the market isn’t just reacting to policy, but to personality. The stock of Digital World Acquisition Corp. (DWAC), which merged with Trump Media & Technology Group (DJT) in March 2024, remains a volatile beast. On November 19, 2025, DWAC was trading at $10.80 in pre-market, up a modest $0.03 (+0.28%) from its previous close of $10.77. A small move, perhaps, but a symbol of the larger, often unpredictable, market landscape shaped by the man himself.
In essence, navigating the markets under the influence of Donald Trump is less about fundamental analysis and more about anticipating the next tweet, the next pronouncement, or the next diplomatic spectacle. It’s a high-stakes game of economic roulette, where the wheel is spun daily, and the only constant is the delightful, bewildering uncertainty. Analysts, investors, and even the occasional rancher are left to decipher the tea leaves, hoping to catch a glimpse of whether today’s policy flip-flop will be a boon or a bust. And so, the show goes on, with the market, like a seasoned performer, adjusting its act to the whims of its most unpredictable impresario.
DISCLAIMER: We read Trump’s posts so you don’t have to. This is comedy meets market data, not financial advice. Not political advice either – we just like charts and chaos.
Elana Harper is a seasoned financial editor and market analyst with over a decade of experience covering global equities, economic trends, and corporate earnings. Known for her sharp insights, Elana specializes in making complex financial topics accessible to a broad audience. She now serves as the Senior Financial Editor at Stock Market Watch, where she oversees daily market coverage and political commentary.